Returning to PARP inhibition: Rechallenge with Bevacizumab in Ovarian Cancer

The KGOG 3056/NIRVANA-R trial demonstrated that niraparib rechallenge combined with bevacizumab may potentially be a promising maintenance strategy in patients with platinum-sensitive recurrent ovarian cancer (PSROC) previously treated with PARPi. With a 68% 6-month progression-free survival (PFS) rate, this combination may synergistically be able to overcome acquired PARPi resistance, particularly in patients with favorable platinum sensitivity.